Amgen reveals more details of denosumab's fracture benefit
This article was originally published in Scrip
Executive Summary
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
You may also be interested in...
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Gilead must conduct another study of cystic fibrosis drug, FDA says
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.
GSK and Xenoport file restless legs drug Solzira in US
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.